These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 18953117)

  • 1. Lessons learned from failed and discontinued clinical trials for the treatment of Alzheimer's disease: future directions.
    Carlsson CM
    J Alzheimers Dis; 2008 Oct; 15(2):327-38. PubMed ID: 18953117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention Trials in Alzheimer's Disease: Current Status and Future Perspectives.
    Wang J; Tan L; Yu JT
    J Alzheimers Dis; 2016; 50(4):927-45. PubMed ID: 26836177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alzheimer's Disease: Lessons Learned from Amyloidocentric Clinical Trials.
    Soejitno A; Tjan A; Purwata TE
    CNS Drugs; 2015 Jun; 29(6):487-502. PubMed ID: 26187557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention studies in Alzheimer's disease: progress towards the development of new therapeutics.
    Coley N; Gallini A; Andrieu S
    CNS Drugs; 2015 Jul; 29(7):519-28. PubMed ID: 26188654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trial design issues in mild to moderate Alzheimer disease.
    Knopman DS
    Cogn Behav Neurol; 2008 Dec; 21(4):197-201. PubMed ID: 19057167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translational medicine lessons from flurizan's failure in Alzheimer's disease (AD) trial: Implication for future drug discovery and development for AD.
    Wan HI; Jacobsen JS; Rutkowski JL; Feuerstein GZ
    Clin Transl Sci; 2009 Jun; 2(3):242-7. PubMed ID: 20443898
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future.
    Cummings J; Ritter A; Zhong K
    J Alzheimers Dis; 2018; 64(s1):S3-S22. PubMed ID: 29562511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.
    Vellas B; Carrillo MC; Sampaio C; Brashear HR; Siemers E; Hampel H; Schneider LS; Weiner M; Doody R; Khachaturian Z; Cedarbaum J; Grundman M; Broich K; Giacobini E; Dubois B; Sperling R; Wilcock GK; Fox N; Scheltens P; Touchon J; Hendrix S; Andrieu S; Aisen P;
    Alzheimers Dement; 2013 Jul; 9(4):438-44. PubMed ID: 23809364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Motivators for Alzheimer's disease clinical trial participation.
    Bardach SH; Holmes SD; Jicha GA
    Aging Clin Exp Res; 2018 Feb; 30(2):209-212. PubMed ID: 28523610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.
    Shoaib M; Kamal MA; Rizvi SMD
    Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new proposal for randomized start design to investigate disease-modifying therapies for Alzheimer disease.
    Zhang RY; Leon AC; Chuang-Stein C; Romano SJ
    Clin Trials; 2011 Feb; 8(1):5-14. PubMed ID: 21335586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and emerging therapies for Alzheimer's disease.
    Nygaard HB
    Clin Ther; 2013 Oct; 35(10):1480-9. PubMed ID: 24139420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond amyloid: the future of therapeutics for Alzheimer's disease.
    Lane RF; Shineman DW; Steele JW; Lee LB; Fillit HM
    Adv Pharmacol; 2012; 64():213-71. PubMed ID: 22840749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recruitment methods for United States Alzheimer disease prevention trials.
    Schneider LS
    J Nutr Health Aging; 2012 Apr; 16(4):331-5. PubMed ID: 22499452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical Discoveries on Multi-Target Approach to Manage Alzheimer's Disease.
    Batool A; Kamal MA; Rizvi SMD; Rashid S
    Curr Drug Metab; 2018; 19(8):704-713. PubMed ID: 29512457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increasing the success rate for Alzheimer's disease drug discovery and development.
    Becker RE; Greig NH
    Expert Opin Drug Discov; 2012 Apr; 7(4):367-70. PubMed ID: 22439785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging therapeutics for Alzheimer's disease.
    Chiang K; Koo EH
    Annu Rev Pharmacol Toxicol; 2014; 54():381-405. PubMed ID: 24392696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease-modifying approaches to Alzheimer's disease: challenges and opportunities-Lessons from donepezil therapy.
    Sabbagh MN; Richardson S; Relkin N
    Alzheimers Dement; 2008 Jan; 4(1 Suppl 1):S109-18. PubMed ID: 18631986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trials in predementia stages of Alzheimer disease.
    Pillai JA; Cummings JL
    Med Clin North Am; 2013 May; 97(3):439-57. PubMed ID: 23642580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?
    Becker RE; Greig NH; Giacobini E
    J Alzheimers Dis; 2008 Oct; 15(2):303-25. PubMed ID: 18953116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.